Have your own idea? Try our Stock Screener
Chinese (SSE) Biotech Industry Analysis
UpdatedApr 08, 2026
DataAggregated Company Financials
Companies75
- 7D2.1%
- 3M-6.3%
- 1Y5.3%
- YTD-4.7%
The Biotech industry is up 2.1% in the last week, with Sunshine Guojian Pharmaceutical (Shanghai) up 8.8%. In the same time, Vcanbio Cell & Gene Engineering was down 12%. This means that the industry has gained 5.3% over the past year. As for the next few years, earnings are expected to grow by 33% per annum.
Industry Valuation and Performance
Has the Chinese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 09 Apr 2026 | CN¥910.9b | CN¥109.9b | CN¥4.7b | 44x | 192.7x | 8.3x |
| Sat, 07 Mar 2026 | CN¥901.4b | CN¥109.6b | CN¥5.5b | 44.4x | 163.5x | 8.2x |
| Mon, 02 Feb 2026 | CN¥940.0b | CN¥106.1b | CN¥3.8b | 50.6x | 249.1x | 8.9x |
| Wed, 31 Dec 2025 | CN¥916.9b | CN¥106.1b | CN¥3.8b | 47.3x | 243x | 8.6x |
| Fri, 28 Nov 2025 | CN¥974.1b | CN¥106.1b | CN¥3.8b | 51x | 258.2x | 9.2x |
| Sun, 26 Oct 2025 | CN¥934.0b | CN¥108.2b | CN¥4.9b | 51.4x | 191.4x | 8.6x |
| Tue, 23 Sep 2025 | CN¥970.1b | CN¥107.5b | CN¥5.1b | 47.7x | 191.9x | 9x |
| Thu, 21 Aug 2025 | CN¥994.1b | CN¥108.8b | CN¥7.0b | 43.6x | 142.9x | 9.1x |
| Sat, 19 Jul 2025 | CN¥949.1b | CN¥112.9b | CN¥8.2b | 42.4x | 115.2x | 8.4x |
| Mon, 16 Jun 2025 | CN¥887.1b | CN¥113.0b | CN¥8.3b | 37.7x | 107x | 7.9x |
| Wed, 14 May 2025 | CN¥812.8b | CN¥113.2b | CN¥8.4b | 35.6x | 96.7x | 7.2x |
| Fri, 11 Apr 2025 | CN¥842.9b | CN¥136.1b | CN¥11.7b | 30.8x | 72.3x | 6.2x |
| Sun, 09 Mar 2025 | CN¥853.0b | CN¥136.2b | CN¥11.6b | 32x | 73.8x | 6.3x |
| Tue, 04 Feb 2025 | CN¥797.7b | CN¥136.0b | CN¥10.8b | 32.4x | 74.1x | 5.9x |
| Thu, 02 Jan 2025 | CN¥825.8b | CN¥136.0b | CN¥10.8b | 33.1x | 76.8x | 6.1x |
| Sat, 30 Nov 2024 | CN¥921.3b | CN¥141.7b | CN¥11.2b | 36.3x | 82.3x | 6.5x |
| Mon, 28 Oct 2024 | CN¥937.3b | CN¥143.1b | CN¥12.0b | 35.3x | 78.2x | 6.5x |
| Wed, 25 Sep 2024 | CN¥752.5b | CN¥154.1b | CN¥14.5b | 30.5x | 52.1x | 4.9x |
| Fri, 23 Aug 2024 | CN¥773.2b | CN¥161.4b | CN¥17.4b | 28.2x | 44.5x | 4.8x |
| Sun, 21 Jul 2024 | CN¥849.4b | CN¥161.1b | CN¥17.3b | 33.9x | 49.1x | 5.3x |
| Tue, 18 Jun 2024 | CN¥877.3b | CN¥161.1b | CN¥17.3b | 32.5x | 50.7x | 5.4x |
| Thu, 16 May 2024 | CN¥954.0b | CN¥161.1b | CN¥17.3b | 38.9x | 55.3x | 5.9x |
| Sat, 13 Apr 2024 | CN¥938.7b | CN¥161.4b | CN¥20.3b | 37.5x | 46.3x | 5.8x |
| Mon, 11 Mar 2024 | CN¥978.7b | CN¥165.5b | CN¥22.1b | 35.6x | 44.3x | 5.9x |
| Wed, 07 Feb 2024 | CN¥908.8b | CN¥167.9b | CN¥21.4b | 30.7x | 42.4x | 5.4x |
| Fri, 05 Jan 2024 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 39.2x | 51x | 6.5x |
| Sun, 03 Dec 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 41.5x | 53.4x | 6.8x |
| Tue, 31 Oct 2023 | CN¥1.1t | CN¥175.3b | CN¥25.0b | 40.5x | 43.4x | 6.2x |
| Thu, 28 Sep 2023 | CN¥1.1t | CN¥170.9b | CN¥25.2b | 42.7x | 42x | 6.2x |
| Sat, 26 Aug 2023 | CN¥965.7b | CN¥171.4b | CN¥27.8b | 36.3x | 34.7x | 5.6x |
| Mon, 24 Jul 2023 | CN¥1.1t | CN¥177.4b | CN¥29.9b | 38.9x | 35.8x | 6x |
| Wed, 21 Jun 2023 | CN¥1.1t | CN¥177.4b | CN¥29.3b | 38.5x | 37x | 6.1x |
| Fri, 19 May 2023 | CN¥1.2t | CN¥177.8b | CN¥29.6b | 40.7x | 38.9x | 6.5x |
| Sun, 16 Apr 2023 | CN¥1.3t | CN¥187.3b | CN¥36.6b | 43.8x | 35.5x | 6.9x |
Price to Earnings Ratio
35.5x
Current Industry PE
- Investors are optimistic on the Chinese Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 193x which is higher than its 3-year average PE of 94.2x.
- The 3-year average PS ratio of 6.8x is lower than the industry's current PS ratio of 8.3x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 49% per year over the last three years,
- Revenues have also declined 16% per year.
- This means overall sales from these companies are declining and profits are subsequently falling as well.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | -0.31% | |
| Healthcare | 1.89% | |
| Biotech | 2.14% | |
| Biotech | 2.14% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688336 Sunshine Guojian Pharmaceutical (Shanghai) | CN¥86.67 | 8.8% +CN¥4.3b | 243.2% | PE18.2x | |
| 688656 HOB Biotech GroupLtd | CN¥141.01 | 7.2% +CN¥596.1m | 85.1% | PE380.9x | |
| 688443 Chongqing Genrix Biopharmaceutical | CN¥29.08 | 5.9% +CN¥590.4m | 9.3% | PS46.2x | |
| 600201 Jinyu Bio-technology | CN¥15.27 | 3.6% +CN¥579.1m | 118.1% | PE165.6x | |
| 688767 Hangzhou Biotest BiotechLtd | CN¥33.86 | 5.6% +CN¥264.8m | 34.3% | PE105.9x |